Category Archives: Take Action

Take action to protect your rights to use your own stem cells

♦ Adult Stem Cells Restore Sight To The Blind

March 13th, 2016 – Stem cell patients are making news! PFSC brings together all the reports on Doug Oliver and Vanna Belton, both of whom have regained vision thanks to a pioneering trial led by Dr. Jeffrey Weiss.

First, THANK YOU! to all PFSC subscribers for responding to the FDA Part 15 Hearing registration drive. As hoped, the overwhelming response caused the FDA to postpone the April 13th hearing, and there will be a collaborative workshop w/ stake holders. We look forward to open dialog with the FDA. More info forthcoming as soon as we learn of it.

Now the leaders in the Senate are looking at ways to advance cellular therapy. Patients will be listened to as constituents. At the end of this post, look for information on how you can support this legislation, which is being introduced on March 15th, 2016. [Update: delayed until March 16th, so we have another day to email our Senators.]

Doug Oliver

Doug Oliver

To help readers understand what this legislation could do for the health of Americans, PFSC will run a series of posts highlighting the positive outcomes from clinical trials, and patient stories. For conditions ranging from orthopedics, to stroke and autoimmune diseases. Starting with this story on vision recovery previously thought to be impossible.

Doug Oliver’s vision has been deteriorating since he was 30 due to a form of macular degeneration called Autosomal Dominant Drusen. By his early 50’s, Doug was legally blind, and could no longer drive or see faces.

Doug’s story was covered by Nashville Fox Affiliate WZTV, in a year-long series of reports by Mikayla Lewis which tracked his recovery from legally blind to regaining his driver’s license. His vision changes are documented in his medical records from exams at Vanderbilt University Eye Institute; he has released these records to the public as part of his effort to spread awareness of this treatment.

Highlighted facts of Doug’s case:

  • May 2015, the time of his first television interview with FOX, (before treatment), his vision was 20/400 in the right eye and 20/2000 in the left.
  • Oct 2015, at the follow-up interview (after treatment in Aug 2015), his vision had improved to 20/40 and 20/40 visual acuity range, which is legal for driving.
  • Dec 2015, Doug received his driver’s license.
  • Mar 2016, his vision is 20/30 in his right eye and 20/40 in the left.
  • Mar 11th, 2016 Mikayla Lewis returns to see Doug taking his wife for a drive “Stem Cell Therapy Helps Blind Man See“.

In his latest interview, Doug addresses a common confusion. When people hear “stem cells” they think of therapies that utilize embryos. The reporter includes an explanation by former Senator Bill Frist, MD that research on use of embryonic cells is fading. Adult stem cells from one’s own tissues are proving to be the safer and more effective method.

Vanna Belton

Vanna Belton

Vanna Belton’s vision was 20/3000 in both eyes, after she lost her sight in a matter of weeks in 2009 due to a severe onset of optic neuritis, leaving her completely blind. Vanna is still considered legally blind, but following stem cell therapy in the SCOTS trial in 2014, she can now see enough to no longer need a white cane. Vanna’s case presentation has been published in Neural Regeneration Research Journal, and is currently being submitted for follow up peer-reviewed publication.

The reports on Vanna’s case span the range from positive, factual, to a little histrionic. Patients considering such an investment in experimental therapy that has not yet reached publication or approval need to have all the information available.

The Baltimore Sun report by Meredith Cohn, an experienced health journalist, falls into the balanced journalism category, exploring the pros and cons. The next two reports are from science blogs, recapping Meredith’s story. Science Alert echoes the balanced tone, while the negative terms like “renegade” indicate the Inverse blog is using sensational terms to attract viewers. Yet the author hedges her bets at the end with “Weiss’ work is important because it’s pushing the frontiers of science well beyond what we even think is possible.”

Is this press release the Principal investigator, Dr. Jeffrey Weiss, a board certified retinal surgeon and ophthalmologist, explains the Florida-based Stem Cell Ophthalmology Treatment Study (SCOTS). It is registered with the National Institutes of Health with identifier NCT01920867. It lists the conditions treated by SCOTS, as well as study contacts. The study uses the patient’s own stem cells obtained under anesthesia from the bone marrow. These cells are injected around and potentially in the eye.

In the above media reports Dr. Weiss states 278 patients have been treated, and 60 percent of his 278 patients with macular degeneration, glaucoma and other diseases have regained some sight.

Like many of the cellular therapies offered in the U.S. the SCOTS trial is a patient-funded clinical trial; in this case treatments cost $21,000, which insurance does not cover because the procedure is investigational. Doug raised the funds for the treatment from his local community and through a GoFundMe campaign. Vanna spent her wedding budget to pay for treatment and got married at the courthouse instead.

The SCOTS trial is tracking patient results and submitting early initial case reports like Doug and Vanna’s to peer-reviewed publications. This is the first step in the process leading to publishing the results on all of the patients to determine safety and efficacy. If results warrant it, the therapy could be approved. Multiple trials and many years are usually required for approval, but the new legislation being introduced to the Senate HELP Committee could speed this approval process.

MARCH 2016 CELLULAR THERAPY LEGISLATION INTRODUCED

Senators Mark Kirk and Susan Collins are poised to introduce this legislation, because they recognize the hardship placed on patients with difficult to treat diseases, who are left with no option but to raise funds for cellular therapy, and many have to travel outside the U.S. to received treatment.

Mar 16, 2016: The Kirk/Collins bill will be introduced to the Senate HELP Committee.
Apr 06, 2016: The bill is scheduled for markup (approximate date).

YOU CAN HELP PASS STEM CELL LEGISLATION

Click TAKE ACTION for step by step instructions and draft letters you can email your Senators today. Your story can make it clear why this bill will help patients, whether you are a patient, or know someone who needs stem cells. If you are in a state that has a Senator on the HELP Committee, we urge you to schedule an in person meeting during recess March 27th-April 4th.

Patient For Stem Cells will be monitoring this legislative process and reporting developments as they happen. This may finally bring together all the stake holders, the regulators, legislators, researchers, physicians and patients, so that cellular therapy finally gets the high priority that a breakthrough therapy deserves.

Please use the share buttons below spread this post far and wide so our Senators get plenty of emails!

If you have a stem cell story you’d like us to cover, or wish to report on your interaction with your Senator, please Contact PFSC.

Talk to PFSC members on Facebook | Twitter | Google+ | LinkedIn

Want to become a member of Patients For Stem Cells? Just subscribe to our blog!


 

♦ FDA Public Hearing On Stem Cell Access – Registration Deadline Jan 8th

Wear this T-Shirt to the FDA hearing!  Available from  Bioinformant.

Wear this T-Shirt to the FDA hearing!
Available from Bioinformant.

Update: Over 600 event registrations arrived at the FDA, causing cancellation of the hearing. Thank you everyone, your voice is being heard! For all the details, see the 3/16/2016 BioInformant post.
———————–
The FDA has announced a 1 day public hearing to obtain input on the four recently issued draft guidances relating to the regulation of stem cell therapy in the U.S. The restrictive proposed regulations will prevent countless patients from receiving this life-changing treatment. The FDA will consider information from medical professional as well as the public/patients on the finalization of these guidances on April 13, 2016.

Read examples here of how stem cell therapy has been making news for saving patients from disabling, even life threatening illness. The FDA regulations would further limit or stop access to these treatments in America.

WE NEED TO LET OUR COLLECTIVE PATIENT VOICE BE HEARD!!!

Step 1: Register for the FDA Public Meeting

April 13, 2016 8:00 a.m. – 5:00 p.m.
FDA’s White Oak Campus
10903 New Hampshire Avenue
Silver Spring, Maryland 20903
Directions
To register by Jan 8th 2015, send an email to: CBERPublicEvents@fda.hhs.gov

Please register even if you can’t attend in person. We are requesting webinar access for those who cannot travel.
Provide the following info in your email.

1. Full name
2. Titles
3. Affiliation
4. Address
5. Email
6. Phone number
7. Your comment

For Affiliation, here are some suggestions:
• Patients For Stem Cells
• Stem Cell Pioneers

Comments are not required, but you can include one about your concerns. Please save it for submitting to the Federal Register. Instruction on how to do this will follow.
Here are some comment examples:

As a “No Option Patient” with a disabling chronic disease, I would like the option to be treated with my own cells, especially when all other FDA approved therapies have failed me. Please consider this when rendering your decision on the minimal manipulation of stem cells.

As a patient who has received cell therapy with quality of life benefits I can attest I wouldn’t be alive today if it wasn’t for the adult stem cell therapy I have received. I should have the right to this therapy here in the U.S. without having to travel offshore.

I am a caregiver of a once vibrant, active and intelligent human being. It is heartbreaking to watch the deterioration of a loved one who could potentially benefit from cell therapy. This a travesty beyond measure.

Step 2: Inform your representative

The FDA is a non-elected appointed regulatory body. Citizens have little recourse to object to the control they are trying to take of the practice of medicine. Please inform your elected Representatives of what is happening.

To find your Representative’s contact and email info, click here.

Step 3: Become an informed advocate

Here is the FDA public notice on the meeting:
Federal Register Notice: Draft Guidances Relating to the Regulation of Human Cells, Tissues, or Cellular or Tissue-Based Products; Public Hearing; Request for Comments

Here are the topics rhat will be addressed at the hearing:

    1) Overview of regenerative cells and potential usefulness to medical practice, explaining the scientific data available for us of non-embryonic stem cells, their safety and ethical acceptance.
    2) Forcing US citizens to leave home as medical tourists for untested therapies.
    3) Importance of the physician’s role in the “Practice of Medicine” and the physician patient covenant.
    4) Patient’s Bill of Rights including access to all potential treatments regardless of costs.
    5) Patient’s “Right to Try” laws and the off label use of regenerative cells.
    6) Economic (a) and Academic loss (b) associated with restrictive regressive regulations
    a) Allowing for patient funded clinical studies in the US.
    b) Establishing general and disease specific patient registries designed to collaboratively advance the science and clinical protocols.
    7) Bioethical concerns associated with delaying/denying the aggressive testing and development of quality of life improving and life saving therapies.
    8) The de facto exclusions of these therapies for children in the US.

Thank you for your efforts!

♦ Patient Power Can Accelerate Access to Stem Cell Therapy

You may know from this blog that Patients For Stem Cells (PFSC) is a grassroots effort by patients who want to advance the progress of stem cell therapy. This therapy is an ideal candidate for the accelerated access programs being called for, from the wave of state laws granting “Right To Try” experimental therapies, to the “21st Century Cures Act” moving quickly through Congress.

AACT.coPFSC is pleased to announce we have joined forces with an organization founded with the goal of accelerating access to life saving cellular therapy, The Alliance for the Advancement of Cellular Therapies (AACT)

We’re inviting PFSC subscribers to join AACT as well. They have generously waived the patient membership fee to kick off this partnership!

To join go to AACT.co, click the Membership option and register for Citizen/Patient Membership – Free!

AACT is organizing the Chicago Stem Cell Showcase Sept 17-18. This is where the doctors and researchers in cellular therapy are gathering to explore “The Dilemma of Difficult Diseases: Cell Therapies to the Rescue?

The Speakers are medical professionals at the forefront of cellular medicine, They need our support for sticking their necks out, in a regulatory environment that has been less than accommodating. We can do this by building a strong member base for AACT.

Members will get access to resources including:

  • Clinical trial information and statistics
  • Regulatory information and advocacy
  • Informative newsletter
  • Patient forums
  • Access to conference videos

After the Chicago conference, the presentation videos are going to be an incredible education resource for members. Take a look at the packed Agenda, you may see your own illness is going to be addressed by an expert in the field.

Cellular therapy is rarely covered by insurance in the U.S. except for blood cancers. Accelerated access programs are needed in the U.S., similar to what Europe and Japan are already adopting. Starting with difficult diseases for which there are few medical options, like ALS, Parkinson’s, Alzheimer’s, Multiple Sclerosis, Critical Limb Ischemia, Stroke, Heart Disease and many more. Tracking results of patients enrolled in accelerated access can speed approval and insurance coverage.

One of the founding members of PFSC, SammyJo Wilkinson, has volunteered to serve as Patient Advisory Board Chairman for AACT. She is a stem cell patient herself, and knows the frustration patients face. “The AACT patient portal is where patients can get the facts on cellular therapy in plain language. Then they can make better decisions before joining a medical trial, or spending money on therapies not yet covered by insurance. I am thrilled to be part of the PFSC and ACCT partnership!”

SammyJo will be communicating with members as the AACT website develops these resources, and will represent patient opinions to the Executive Board – especially on FDA issues. If you have opinions or want to get involved now in the advocacy process, send SammyJo an email at info@AACT.co

By becoming a member and inviting others to join, you can “AACT Now” to make a difference!

We encourage you to join the discussion in social media and give us your feedback!

AACT Facebook Twitter Google+ LinkedIn AACT.co

PFSC Facebook Twitter
Want to become a member of Patients For Stem Cells? Just subscribe to our blog!